GentiBio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 61

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $157M

  • Investors
  • 8

GentiBio General Information

Description

Developer of a modular engineering platform designed to develop therapies to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company's proprietary autologous and allogeneic platform integrates key complementary technologies needed to restore immune tolerance and overcome limitations in existing regulatory T-cell therapeutics, enabling healthcare providers to address the fundamental cause of many diseases that result from overshooting and malfunctioning of the immune system.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 150 Cambridgepark Drive
  • 9th Floor
  • Cambridge, MA 02140
  • United States
+1 (301)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 150 Cambridgepark Drive
  • 9th Floor
  • Cambridge, MA 02140
  • United States
+1 (301)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GentiBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 11-Aug-2021 $157M Completed Pre-Clinical Trials
1. Seed Round 05-Aug-2020 Completed Pre-Clinical Trials
To view GentiBio’s complete valuation and funding history, request access »

GentiBio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view GentiBio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

GentiBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a modular engineering platform designed to develop therapies to treat autoimmune, alloimmune, autoinflammat
Drug Discovery
Cambridge, MA
61 As of 2024

London, United Kingdom
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GentiBio Competitors (3)

One of GentiBio’s 3 competitors is Quell Therapeutics, a Venture Capital-Backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Quell Therapeutics Venture Capital-Backed London, United Kingdom
Sonoma Biotherapeutics Venture Capital-Backed San Francisco, CA
Lava Therapeutics Formerly VC-backed Utrecht, Netherlands
You’re viewing 3 of 3 competitors. Get the full list »

GentiBio Patents

GentiBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213230-A1 Chimeric t cell receptors targeting butyrophilin-like proteins Pending 31-Mar-2025
WO-2026060042-A1 Membrane-anchored nk cell inhibitory receptor engagers Pending 10-Sep-2024
WO-2026035928-A1 Regulatory t cells expressing chimeric antigen receptors Pending 07-Aug-2024
EP-4654981-A1 Engineered repair regulatory t cells Pending 27-Jan-2023
JP-2026503660-A Engineered repair regulatory t cells Pending 27-Jan-2023 C12N5/0637
To view GentiBio’s complete patent history, request access »

GentiBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GentiBio Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Avidity Partners Asset Manager Minority
Benaroya Research Institute Corporation Minority
Matrix Capital Management Hedge Fund Minority
Seattle Children's Hospital Corporation Minority
T1D Fund Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

GentiBio FAQs

  • When was GentiBio founded?

    GentiBio was founded in 2020.

  • Where is GentiBio headquartered?

    GentiBio is headquartered in Cambridge, MA.

  • What is the size of GentiBio?

    GentiBio has 61 total employees.

  • What industry is GentiBio in?

    GentiBio’s primary industry is Drug Discovery.

  • Is GentiBio a private or public company?

    GentiBio is a Private company.

  • What is the current valuation of GentiBio?

    The current valuation of GentiBio is .

  • What is GentiBio’s current revenue?

    The current revenue for GentiBio is .

  • How much funding has GentiBio raised over time?

    GentiBio has raised $177M.

  • Who are GentiBio’s investors?

    Avidity Partners, Benaroya Research Institute, Matrix Capital Management, Seattle Children's Hospital, and T1D Fund are 5 of 8 investors who have invested in GentiBio.

  • Who are GentiBio’s competitors?

    Quell Therapeutics, Sonoma Biotherapeutics, and Lava Therapeutics are competitors of GentiBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process